Drug profile · INN
indomethacin
INDO-LEMMON
indomethacin (INDO-LEMMON) is a cyclooxygenase inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: rectal. Current US regulatory status: approved.
Drug details — indomethacin
- US status
- approved
- Class
- —
- Route
- RECTAL
- Patents
- 0
- Programs
- 1
- Data quality
- 0.89
Quick answer
indomethacin (INDO-LEMMON) is a cyclooxygenase inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: rectal. Current US regulatory status: approved.
Key facts
Mechanism of action
Cyclooxygenase inhibitor
Primary target: Cyclooxygenase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is indomethacin?
indomethacin (INDO-LEMMON) is a cyclooxygenase inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: rectal. Current US regulatory status: approved.
What is the brand name for indomethacin?
INDO-LEMMON is a marketed brand name for indomethacin. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of indomethacin?
indomethacin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.